editor@ajptr.com
9409046853
e-ISSN: 2249-3387
logo

American Journal of PharmTech Research

LoginTrack
Published

Formulation Development of a Transdermal Self-Microemulsifying Drug Delivery System of Bosutinib

Kalpesh Patel
,
Nirav Patel

Published in December 2022 Issue 6 (Vol. 12, Issue 6, 2022)

Formulation Development of a Transdermal Self-Microemulsifying Drug Delivery System of Bosutinib - Issue cover

Keywords

Self-microemulsifyingBosutiniboleic acidLabrasoltopical gel.

Abstract

Tyrosine kinase inhibitors treat chronic myeloid leukemia but have many negative effects. These BCS Class II or IV medicines have low oral bioavailability due to poor solubility, permeability, or both. As P-glycoprotein substrates and hepatic presystemic metabolism inactivators, these medicines have another drawback. The present work sought to overcome the limitations of tyrosine kinase inhibitor bosutinib. A transdermal system with the medication put into a SMEDDS was created. The investigation began with solubility and emulsification studies to choose the proper oil (oleic acid), surfactant (Tween 20), and cosurfactant (Transcutol® P). The microemulsion zone was identified using ternary phase diagrams. The resultant SMEDDS exhibited a narrow polydispersity index and a droplet size of 45.66 ± 2.4 nm. The formulation's zeta potential prevented aggregation during storage, as shown by thermodynamic stability investigations under physical and thermal stress. Dispersibility and dilution experiments showed that the formulation formed the microemulsion instantly in vivo. BOS-loaded liquid SMEDDS was gelled with 2% HPMC K15M to make G-SNEDDS. The liquid SMEDDS and G-SMEDDS had similar properties. In vitro dissolution showed that near to 100% drug release could be achieved in 30 mins, compared to 5–6% for the simple medication. The formulation's in vitro permeability testing employing an artificial membrane demonstrated a 2.18-fold increase in drug penetration compared to the basic drug suspension.

References

  1. [1]1. Homayun B, Lin X, Choi HJ, 2019. Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals. Pharmaceutics. 11(3):129. doi:10.3390/pharmaceutics11030129
  2. [2]2. Shreya AB, Raut SY, Managuli RS, Udupa N, Mutalik S, 2018. Active Targeting of Drugs and Bioactive Molecules via Oral Administration by Ligand-Conjugated Lipidic Nanocarriers: Recent Advances. AAPS PharmSciTech. 20(1):15. doi:10.1208/s12249-018-1262-2
  3. [3]3. Wadhwa J, Nair A, Kumria R, 2011. Self-emulsifying therapeutic system: a potential approach for delivery of lipophilic drugs. Braz J Pharm Sci. 47(3):447-465. doi:10.1590/S1984-82502011000300003
  4. [4]4. Pouton CW, 2000. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and ‘self-microemulsifying’ drug delivery systems. Eur J Pharm Sci. 11:S93-S98. doi:10.1016/S0928-0987(00)00167-6
  5. [5]5. Cohen P, 2002. Protein kinases--the major drug targets of the twenty-first century? Nat Rev Drug Discov. 1(4):309-315. doi:10.1038/nrd773
  6. [6]6. Cohen P, Cross D, Jänne PA, 2021. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov.1-19. doi:10.1038/s41573-021-00195-4
  7. [7]7. Paul TR, Uppin SG, Uppin MS, Jacob RT, Rao DR, Rajappa SJ, 2010. Evaluation of Cytopenias Occurring in Imatinib Treated Chronic Myeloid Leukemia (CML) Patients. Indian J Hematol Blood Transfus Off J Indian Soc Hematol Blood Transfus. 26(2):56-61. doi:10.1007/s12288-010-0030-6
  8. [8]8. Kerkelä R, Grazette L, Yacobi R, 2006. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 12(8):908-916. doi:10.1038/nm1446
  9. [9]9. de Lavallade H, Apperley JF, Khorashad JS, 2008. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol Off J Am Soc Clin Oncol. 26(20):3358-3363. doi:10.1200/JCO.2007.15.8154
  10. [10]10. Cortes JE, Baccarani M, Guilhot F, 2010. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol Off J Am Soc Clin Oncol. 28(3):424-430. doi:10.1200/JCO.2009.25.3724
  11. [11]11. Herbrink M, Nuijen B, Schellens JHM, Beijnen JH, 2015. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treat Rev. 41(5):412-422. doi:10.1016/j.ctrv.2015.03.005
  12. [12]12. Abbas R, Hsyu PH, 2016. Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib. Clin Pharmacokinet. 55(10):1191-1204. doi:10.1007/s40262-016-0391-6
  13. [13]13. Hochhaus A, Gambacorti-Passerini C, Abboud C, 2020. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia. 34(8):2125-2137. doi:10.1038/s41375-020-0915-9
  14. [14]14. Inoue A, Imamura CK, Shimada H, 2020. Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia. J Pediatr Pharmacol Ther JPPT. 25(8):742-745. doi:10.5863/1551-6776-25.8.742
  15. [15]15. Doan V, Wang A, Prescott H, 2015. Bosutinib for the treatment of chronic myeloid leukemia. Am J Health Syst Pharm. 72(6):439-448.
  16. [16]16. Cortes JE, Apperley JF, DeAngelo DJ, 2018. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. J Hematol OncolJ Hematol Oncol. 11(1):143. doi:10.1186/s13045-018-0685-2
  17. [17]17. O’Brien Z, Moghaddam MF, 2017. A Systematic Analysis of Physicochemical and ADME Properties of All Small Molecule Kinase Inhibitors Approved by US FDA from January 2001 to October 2015. Curr Med Chem. 24(29):3159-3184. doi:10.2174/0929867324666170523124441
  18. [18]18. Pattewar S, Kasture SB, P VV, e, Patil DN, Sharma SK, 2018. Development and Optimization of Piroxicam-loaded Solid Self-micro emulsifying Drug Delivery System. Indian J Pharm Sci. 80(2):350-358. doi:10.4172/pharmaceutical-sciences.1000364
  19. [19]19. Ramkanth S, Kumar AK, Thiruvengadarajan VS, Gopinath C, 2016. Preparation and characterization of self-microemulsifying drug delivery system of carvedilol. Int J Reseach Pharm Sci. 7(2):157-163.
  20. [20]20. Grace X, Krishnaraj K, Darsika C, Pushpalatha H, Chaudhari P, 2018. A NOVEL APPROACH FOR TOPICAL GEL CONTAINING SMEDDS LOADED WITH HERBAL DRUG. Int J Pharm Sci Res. 9(3):1129-1140. doi:10.13040/IJPSR.0975-8232.9(3).1129-40
  21. [21]21. Bachhav YG, Patravale VB, 2009. Microemulsion based vaginal gel of fluconazole: formulation, in vitro and in vivo evaluation. Int J Pharm. 365(1-2):175-179. doi:10.1016/j.ijpharm.2008.08.021
  22. [22]22. Shinde U, Pokharkar S, Modani S, 2012. Design and Evaluation of Microemulsion Gel System of Nadifloxacin. Indian J Pharm Sci. 74(3):237-247. doi:10.4103/0250-474X.106066
  23. [23]23. Dalmora ME, Dalmora SL, Oliveira AG, 2001. Inclusion complex of piroxicam with beta-cyclodextrin and incorporation in cationic microemulsion. In vitro drug release and in vivo topical anti-inflammatory effect. Int J Pharm. 222(1):45-55. doi:10.1016/s0378-5173(01)00692-5
  24. [24]24. Shishu, Rajan S, Kamalpreet, 2009. Development of novel microemulsion-based topical formulations of acyclovir for the treatment of cutaneous herpetic infections. AAPS PharmSciTech. 10(2):559-565. doi:10.1208/s12249-009-9242-1
  25. [25]25. Khan AW, Kotta S, Ansari SH, Sharma RK, Ali J, 2012. Potentials and challenges in self-nanoemulsifying drug delivery systems. Expert Opin Drug Deliv. 9(10):1305-1317. doi:10.1517/17425247.2012.719870
  26. [26]26. Morris ER, 1977. Molecular Origin of Xanthan Solution Properties. In: Extracellular Microbial Polysaccharides. Vol 45. ACS Symposium Series. AMERICAN CHEMICAL SOCIETY; 81-89. doi:10.1021/bk-1977-0045.ch006
  27. [27]27. Chandak AR, Verma PRP, 2008. Development and Evaluation of HPMC Based Matrices for Transdermal Patches of Tramadol. Clin Res Regul Aff. 25(1):13-30. doi:10.1080/10601330701885066
  28. [28]28. Carvalho FC, Barbi MS, Sarmento VHV, Chiavacci LA, Netto FM, Gremião MPD, 2010. Surfactant systems for nasal zidovudine delivery: structural, rheological and mucoadhesive properties. J Pharm Pharmacol. 62(4):430-439. doi:10.1211/jpp.62.04.0004
  29. [29]29. Bousmina M, 1999. Rheology of polymer blends: linear model for viscoelastic emulsions. Rheol Acta. 38(1):73-83. doi:10.1007/s003970050157
  30. [30]30. Peltola S, Saarinen-Savolainen P, Kiesvaara J, Suhonen TM, Urtti A, 2003. Microemulsions for topical delivery of estradiol. Int J Pharm. 254(2):99-107. doi:10.1016/s0378-5173(02)00632-4
  31. [31]31. Kreilgaard M, 2002. Influence of microemulsions on cutaneous drug delivery. Adv Drug Deliv Rev. 54 Suppl 1:S77-98. doi:10.1016/s0169-409x(02)00116-3
  32. [32]32. Chen H, Chang X, Du D, Li J, Xu H, Yang X, 2006. Microemulsion-based hydrogel formulation of ibuprofen for topical delivery. Int J Pharm. 315(1-2):52-58. doi:10.1016/j.ijpharm.2006.02.015

Authors (2)

Kalpesh Patel

B K Mody Government Pharmacy C...

View all publications →

Nirav Patel

Department of Pharmaceutics, S...

View all publications →

Download Article

PDF

Best for printing and citation

File size: 0.7 MB
Format: PDF

Download Article

PDF

Best for printing and citation

File size: 0.7 MB
Format: PDF

Article Information

Published in:

December 2022 Issue 6 (Vol. 12, Issue 6, 2022)

AJPTR6120012

AJPTR-02-002462

191-210

2022-12-25

JATS XML

Article Impact

Views:5,032
Downloads:1,550

How to Cite

Patel & Patel (2022). Formulation Development of a Transdermal Self-Microemulsifying Drug Delivery System of Bosutinib. American Journal of PharmTech Research, 12(6), 191-210. https://ajptr.com/articles/AJPTR6120012

Article Actions

Whatsapp